When a cut-off for positivity was set at ≥30% of tumoral cells (this cut-off will be used throughout the study), 109/138 (79%) of DLBCL cases were considered positive for EBI3, whereas all BL cases were negative (Figure 2B). This evidence concerns the gene EBI3 and diffuse large B-cell lymphoma.